astrazeneca-oxford
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
Rapid development of a globally distributed, adenovirus-vectored COVID-19 vaccine, initially offered at a non-profit cost, leveraging a unique academic-pharma partnership model.
Description Brand's website · 2026-10-04
A collaborative effort between the pharmaceutical giant AstraZeneca and the University of Oxford, primarily known for developing one of the first widely distributed COVID-19 vaccines, ChAdOx1 nCoV-19 (AZD1222). This partnership combined Oxford's academic research prowess in vaccinology with AstraZeneca's global development, manufacturing, and distribution capabilities.
Offerings
Core capabilities Brand's website · 2026-10-04
ChAdOx1 nCoV-19 (AZD1222 / Vaxzevria) COVID-19 vaccine
Pricing Brand's website · 2026-10-04
Non-profit pricing during the pandemic; commercial pricing expected post-pandemic.
Audience
Target industry Brand's website · 2026-10-04
Global public health, national governments, healthcare systems worldwide, particularly focusing on broad access and distribution during the pandemic.
Landscape
Competitors Brand's website · 2026-10-04
- Pfizer-BioNTech
- Moderna
- Johnson & Johnson (Janssen)
- Novavax
- Sanofi Pasteur
- GSK (GlaxoSmithKline)
Is this your business?
The information above is publicly sourced — assembled by Optimly from astrazeneca-oxford's website and public pages.
Claim this profile to publish your own verified Business Profile and speak for astrazeneca-oxford across the index.
Claim astrazeneca-oxford — free →Page last updated 2026-10-17.